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Irbesartan is projected to be cost and life saving in a Spanish
setting for treatment of patients with type 2 diabetes, hyperten-
sion, and microalbuminuria.
Objectives. The purpose of this study was to project the cu-
mulative incidence of end-stage renal disease (ESRD), life ex-
pectancy, and costs in a Spanish setting of treating patients with
diabetes, hypertension, and microalbuminuria with either stan-
dard hypertension treatment alone or standard hypertension
treatment plus irbesartan 300 mg daily.
Methods. A peer-reviewed, published Markov model that
simulated progression from microalbuminuria to nephropathy,
doubling of serum creatinine, ESRD, and all-cause mortality
in patients with hypertension, type 2 diabetes, and microalbu-
minuria was adapted to a Spanish setting. Two strategies were
compared: (1) irbesartan versus (2) standard hypertension care
with comparable blood pressure control; both began in diabetic
hypertensive subjects with microalbuminuria. Cumulative inci-
dence of ESRD, costs, and life expectancy were projected for a
hypothetical cohort of 1000 subjects. Future costs and life ex-
pectancy were discounted at 3% yearly. A 25-year time horizon
and third party payer perspective were used.
Results. When compared to standard blood pressure control,
irbesartan was projected to reduce the cumulative incidence of
ESRD from (mean ± standard deviation) 24 ± 1% to 9 ± 2%,
save €11,082 ± 2,996, and add 1.40 ± 0.27 life years per treated
patient. The superiority of irbesartan over standard care was
robust under a wide range of plausible assumptions.
Conclusion. Treating patients with hypertension, microalbu-
minuria, and type 2 diabetes with irbesartan was projected to
reduce the incidence of ESRD, extend life, and reduce costs.
The incidence and prevalence of end-stage renal dis-
ease (ESRD) with type 2 diabetes as the major underlying
cause is increasing rapidly in Spain [1, 2], and will worsen
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as the incidence and prevalence of diabetes in Spain ex-
plodes to almost epidemic proportions [3].
Several recent trials reported the blood pressure–
independent renoprotective effects of angiotensin recep-
tor antagonist treatment on the progression of various
stages of renal disease in patients with hypertension and
type 2 diabetes [4–6].
In the Irbesartan Reduction of Microalbuminuria-2
(IRMA-2) study [4], a renoprotective effect of the an-
giotensin II receptor antagonist irbesartan was demon-
strated in type 2 diabetic patients with microalbuminuria,
protecting patients against the transition from microal-
buminuria to overt nephropathy. The Irbesartan in Dia-
betic Nephropathy Trial (IDNT) [5] demonstrated that
irbesartan is renoprotective in type 2 patients with dia-
betes and advanced nephropathy, preventing doubling of
serum creatinine (DSC) and ESRD.
A computer simulation model has recently been devel-
oped which uses clinical data from both trials, as well as
supplementary data drawn from other published sources,
to perform cost consequence analyses of the use of irbe-
sartan in patients with hypertension, nephropathy, and
type 2 diabetes. The technical details, including model
structure, data sources, transition probabilities, and as-
sumptions have been reported elsewhere [7].
The aim of the current study was to incorporate costs
and appropriate clinical data from Spain into this model
to determine the economic and clinical impact of irbesar-
tan treatment in patients with microalbuminuria, hyper-
tension, and type 2 diabetes in a Spanish setting.
METHODS
A Markov-based Monte Carlo computer simulation
model was programmed using DATA Pro software
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Table 1. Summary results
Years Life Life expectancy Cost savings
free of Cumulative expectancy vs. control 25-year vs. control
ESRDa incidence ESRD % yearsa yearsa costs €a €a
Control 13.44 24 14.78 (11.53) − €25,119 −
Irbesartan 15.66 9 16.13 (12.37) 1.40 (0.84) €14,038 €11,082
Control, standard antihypertensive medications excluding ACE inhibitors, other angiotensin II receptor antagonists, and dihydropyridine calcium channel blockers
with equivalent blood pressure control. Undiscounted life expectancy (with discounted life expectancy in brackets) and mean 25-year costs per patient (discounted at
3% annually) are shown.
aMean outcome per patient.
(TreeAge Software, Inc., Williamstown, MA, USA). The
model simulated the progression of patients with type
2 diabetes and hypertension from microalbuminuria
(24-hour UAE 20–199 lg/min) to early overt nephropa-
thy (UAE 200 lg/min to median UAE 1900 mg/24-hours);
advanced overt nephropathy (median UAE on entry 1900
mg/24-hours); DSC; ESRD treated with either dialysis
or renal transplant; and death. In order to deal with
uncertainty in multiple parameters used in the model,
second-order Monte Carlo simulation was performed [8,
9] to calculate the mean, median, standard deviations,
and 95% confidence intervals of the cumulative incidence
of ESRD, life expectancy, and costs by randomly draw-
ing probabilities of key events from distributions taken
from the IRMA-2 trial and the IDNT [4, 5]. Key transi-
tion probabilities, ESRD-related outcomes, and Spanish
costs that were incorporated in the model have been de-
scribed in detail elsewhere [7, 10]. Two treatment choices
were simulated for diabetic hypertensive patients with
microalbuminuria: (1) “irbesartan”—irbesartan 300 mg
daily; and (2) standard antihypertensive medications as
required to achieve a target blood pressure of <135/85
mm Hg [excluded angiotensin-converting enzyme (ACE)
inhibitors, other angiotensin II receptor antagonists, and
dihydropyridine calcium channel blockers]. Outcomes
calculated were the cumulative incidence of ESRD, the
number of days of ESRD avoided, projected life ex-
pectancy, and long-term costs of irbesartan and ESRD
treatment. Future costs were discounted at 3% annually,
and both undiscounted and discounted (3% annually) life
expectancy were calculated. Sensitivity analysis was per-
formed on key variables as described previously [7].
RESULTS
Compared to control, use of irbesartan delayed the on-
set of ESRD, reduced the cumulative incidence of ESRD,
increased life expectancy, and led to overall cost savings
(Table 1). Early use of irbesartan in patients with type
2 diabetes, hypertension, and microalbuminuria is there-
fore efficient.
Irbesartan treatment delayed the progression from mi-
croalbuminuria to more severe stages of diabetic renal
disease; thus, patients spent more years in the state of
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Fig. 1. Mean number of years per patient spent in each disease state
with either standard blood pressure control or irbesartan treatment.
Control, standard antihypertensive medications excluding ACE in-
hibitors, other angiotensin II receptor antagonists, and dihydropyridine
calcium channel blockers with equivalent blood pressure control. Irbe-
sartan, standard antihypertensive medications plus 300 mg irbesartan
daily, started when patients have microalbuminuria.
microalbuminuria, and less in early and advanced pro-
teinuria, DSC, or ESRD states (where the annual risk of
death was higher than that of patients who remained in
the state of microalbuminuria) when treated with irbe-
sartan (Fig. 1).
The cumulative incidence of ESRD was reduced from
(mean ± standard deviation) 24 ± 1% to 9 ± 2%
with irbesartan versus standard antihypertension treat-
ment. The use of irbesartan led to 321 avoided days of
ESRD. Undiscounted life expectancy was improved from
14.78 ± 0.02 to 16.18 ± 0.26 years (an improvement of
1.40 ± 0.27 years for irbesartan treatment versus standard
antihypertension treatment). Discounted life expectancy
was improved by 0.84 ± 0.15 years. Costs per patient were
reduced from €25,119 ± 1,742 with standard hyperten-
sion treatment to €14,038 ± 2,292 with irbesartan (cost
savings after 25 years of €11,082 ± 2,996 per patient). Sen-
sitivity analysis revealed that all conclusions were robust
under a wide range of plausible assumptions.
DISCUSSION
Treatment of ESRD is very expensive; thus, any in-
tervention that delays or prevents the development of
ESRD has the potential to be cost saving or cost effec-
tive. Our results predict not only substantial economic
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savings when irbesartan is used to treat patients with type
2 diabetes, hypertension, and microalbuminuria, but life-
changing improvements in patient outcome, showing the
importance of early treatment with irbesartan in these
patients. The finding of improved effectiveness while ac-
tually saving money is an unusual scenario these days
because most medical advances occur at an increased
cost. Our study only considered the direct medical costs
of irbesartan and ESRD treatment, leading to an un-
derestimation of the overall cost savings from a societal
perspective. We did not take indirect costs due to loss
of productivity secondary to early retirement, sick leave,
and premature death into account. If indirect costs had
been considered, the cost savings expected with irbesar-
tan would have been substantially higher. Thus, both pay-
ers, as a group responsible for providing health care, and
patients, whose lives are prolonged by delaying or avoid-
ing ESRD, benefit from irbesartan use.
A previous analysis based on the IDNT study, which
incorporated Spanish economic and clinical data, demon-
strated that irbesartan treatment started at a later stage of
renal disease in patients with advanced overt nephropa-
thy, hypertension, and type 2 diabetes also led to delay in
the onset of ESRD, improvements in life expectancy, and
cost savings due to avoided ESRD compared to stan-
dard hypertension treatment or amlodipine [10]. These
results, along with the results of the current study, support
both early intervention with irbesartan (patients with
microalbuminuria) and late intervention (patients with
overt nephropathy), both of which lead to life and cost
savings.
One of the main limitations of the present study re-
lates to the fact that the model does not consider ACE
inhibitors, beta-blockers, or other angiotensin II recep-
tor blockers as treatments for type 2 diabetes patients
with hypertension and microalbuminuria. The control
arm of the IRMA-2 included commonly used antihy-
pertensive treatment [diuretics, beta blockers, calcium
channel blockers (except dihydropyridines)] and central
alpha antagonists to achieve the target blood pressure of
<135/85 mm Hg [4]. Nevertheless, no head-to-head clin-
ical comparisons of irbesartan and ACE inhibitors, beta-
blockers, or other angiotensin II receptor blockers have
been published in this population at the time of writing,
making direct comparison in the modeling setting diffi-
cult. The cost-effectiveness of angiotensin receptor block-
ers versus ACE inhibitors will be particularly interesting
when appropriate clinical data become available.
CONCLUSION
This modeling study provides supportive evidence for
the use of irbesartan in patients with type 2 diabetes, hy-
pertension, and microalbuminuria in a Spanish setting.
Early intervention with irbesartan was identified as an
efficient time point at which irbesartan treatment for re-
nal disease associated with type 2 diabetes and hyperten-
sion should be initiated. Irbesartan initiated in the early
stages of diabetic nephropathy was predicted to lead to
decreased incidence of ESRD, increased life expectancy,
and cost savings due to avoided ESRD.
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